Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral encapsulated FMT for chronic active ulcerative colitis
ACTRN12619000611123Phase 2Terminated
- Sponsor
- The University of Sydney
- Start
- Aug 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Lyophilized faecal microbiota transplantation with Placebo (2 arms). Primary endpoint: Clinical remission and either endoscopic remission or response by total Mayo score. Started Aug 2019; status: terminated.
02
Drugs
allogeneic fecal microbiota
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ACTRN12619000611123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000611123.